口服钙通道阻滞剂的应用分析  

Analysis of Oral Calcium Channel Blockers Application

作　　者：陈文秀[1] 谭献文[1] 

机构地区：[1]广东省广州市第一人民医院药剂科,广东广州510180

出　　处：《今日药学》2009年第5期31-33,共3页Pharmacy Today

摘　　要：目的了解口服钙通道阻滞剂应用现状和发展趋势。方法对2004年至2007年本院口服钙通道阻滞剂消耗品种、金额、用药频度(DDDs)进行统计分析。结果口服钙通道阻滞剂的用药金额和DDDs值呈逐渐增长趋势。金额年平均增长率为6.79%、4.74%和30.66%,DDDs的增长率为7.48%、6.39%和30.46%。用药金额前3名依次为苯磺酸氨氯地平(络活喜)、非洛地平缓释片(波依定)、硝苯地平控释片(拜新同)。结论使用口服钙通道阻滞剂的结构和层次比较合理,符合我国目前口服钙通道阻滞剂的发展现状。Objective To investigate the current situation and developing trend of the oral calcium channel blockers used in our hospital. Methods To account and analyze consumptive varieties, sum of money, the defined daily doses （DDDs） and the daily drug cost （DDC） of calcium channel blockers that were used in No. 1 people＇ s hospital of Guangzhouduring the period 2004 - 2007. Results The sum of money and DDDs of calcium channel blockers increased year by year. The average annual increasing rate of sum of money was 6.79%, 4.74%, and 30.66%, and the average annual increasing rate of DDDs of calcium channel blockers was 7.48%, 6.39%, and 30.46%, respectively during the period 2004 -2007. The top 3 drugs in the list of sum of money were as follow： Amolodipine, Felodipine, and Nifedipine. Conclusion The structure and gradation of the application of calcium channel blockers in our hospital is rational, and conform with the developmentcondition of calcium channel blockers in China.

关 键 词：钙通道阻滞剂 限定日剂量 应用分析 

分 类 号：R972[医药卫生—药品]